LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Home・Elenco Azioni・Crinetics Pharmaceuticals Inc
Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

34.46 -1.57

Fortemente da comprare

Aggiornamento del prezzo 10 giu 2026, 19:59 UTC

AcquistaVendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

33.94

Massimo

35.79

Metriche Chiave

By Trading Economics

Entrata

-5M

-128M

Vendite

6.8M

11M

EPS

-1.23

Margine di Profitto

-1,191.029

Dipendenti

594

EBITDA

-18M

-139M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+152.04% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-878M

3.5B

Apertura precedente

36.03

Chiusura precedente

34.46

Notizie sul Sentiment di mercato

By Acuity

61%

39%

281 / 344 Classifica in Healthcare

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 giu 2026, 23:36 UTC

Utili

Correction to Oracle Reports Higher 4Q Profit Article

DJ

LeggI

10 giu 2026, 23:19 UTC

Azioni calde

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

LeggI

10 giu 2026, 23:09 UTC

I principali Market Mover

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

LeggI

10 giu 2026, 23:04 UTC

Utili

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

LeggI

10 giu 2026, 20:44 UTC

I principali Market Mover

Caterpillar Raises Quarterly Dividend 8%

DJ

LeggI

10 giu 2026, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Should Take No Options Off The Table

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

LeggI

10 giu 2026, 23:48 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

LeggI

10 giu 2026, 23:47 UTC

Discorsi di Mercato

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

LeggI

10 giu 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

LeggI

10 giu 2026, 23:46 UTC

Acquisizioni, Fusioni, Takeovers

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

DJ

LeggI

10 giu 2026, 23:38 UTC

Discorsi di Mercato

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

LeggI

10 giu 2026, 23:32 UTC

Discorsi di Mercato

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

LeggI

10 giu 2026, 23:20 UTC

Discorsi di Mercato

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

LeggI

10 giu 2026, 22:05 UTC

Discorsi di Mercato

Correction to Bank of Canada Stays on Hold Market Talk

DJ

LeggI

10 giu 2026, 21:57 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:52 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:35 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 21:22 UTC

Utili

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:39 UTC

Discorsi di Mercato
Utili

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

LeggI

10 giu 2026, 20:34 UTC

Utili

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Utili

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

DJ

LeggI

10 giu 2026, 20:33 UTC

Discorsi di Mercato
Utili

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

LeggI

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

152.04% in crescita

Previsioni per 12 mesi

Media 88.14 USD  152.04%

Alto 97 USD

Basso 81 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

281 / 344 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Altri titoli del settore

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat